

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,867,180
APPLICATION NO. : 09/807,148
ISSUE DATE : March 15, 2005
INVENTORS : Tosato *et al.*

Page 1 of 2

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

Column 5, line 63, "circles) B" should read -- circles). B--.

Column 6, line 8, "130 m²" should read --130 mm²--.

Column 6, line 11, "100 µl/dose,x36" should read --100 µl/dose x36--.

Column 7, line 24, "(10x10⁶ cell/mouse)" should read --(10x10⁶ cell/mouse)--.

Column 7, line 44, "120-1 80" should read -- 120-180--.

Column 14, line 33, "pH 83" should read -- pH 8.3--.

Column 14, line 37, "Na₂ HPO₄" should read --Na₂HPO₄--.

Column 14, line 38, "factions" should read --fractions--.

Column 15, line 12, "8M" should read --8 M--.

Column 16, line 54 "pelleted. and" should read --pelleted, and--.

Column 16, line 66, "kinetic-QCL assay" should read -- kinetic-QCLTM assay--.

Column 18, line 9, "(25 mg/ml)" should read -- (25 ng/ml)--.

Column 18, line 17, "triplicate" should read -- triplicate--.

Column 18, line 18, "triplicate" should read -- triplicate--.

Column 18, line 19, "mean" should read -- mean--.

Column 22, line 11, Table 4, is missing the "Inhibition percentage value" for the first line. Thus, "1.^a None 142 " should read --1.^a None 142 44--.

Column 23, line 30, "days/week;" should read --"days/week);--.

Column 23, line 45, "(FIG. 3D)." should read --(FIG 3D),--.

Column 24, line 10. "tumor" should read --tumors--.

Column 25, line 20, "(30 µg/day;" should read --(30 µg/day);--.

Column 26, line 12, "red" should read --rad--.

Column 26, line 54, "Vivo" should read --Vivo,--.

Column 26, line 57, "turner" should read --tumor--.

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland Oregon, 97204

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,867,180
APPLICATION NO. : 09/807,148
ISSUE DATE : March 15, 2005
INVENTORS : Tosato *et al.*

Page 2 of 2

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 27, line 16, "Interleukin-12" should read --Interleukin-12.--.

Column 28, line 19, "10)" should read -- 10).--.

Column 28, line 33 "amino jet acid" should read --amino acid--.

Column 31, line 3 "fist" should read --first--.

Column 32, line 23 "supra (Seq." should read --supra) (Seq.--.

Column 33, line 44, "may be" should read --may--.

Column 33, line 45, "may be" should read --may--.

Column 33, line 62, "(IN) γ ," should read --IFN) γ --.

Column 34, line 61, "treatment diseases" should read --treatment of diseases--.

In the Claims:

Column 61, Claim 18, line 40, "(TNF) α ," should read --(TNF)- α --.

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland Oregon, 97204

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tosato *et al.*

Patent No. 6,867,180

Issued: March 15, 2005

Application No. 09/807,148

Filed: April 5, 2001

Confirmation No. 2215

FILED VIA EFS

For: USE OF CALRETICULIN AND
CALRETICULIN FRAGMENTS TO
INHIBIT ENDOTHELIAL CELL
GROWTH AND ANGIOGENESIS, AND
SUPPRESS TUMOR GROWTH

Examiner: Misook Yu, Ph.D.

Art Unit: 1642

Attorney Reference No. 4239-58378-01

FILED VIA THE ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR CERTIFICATE OF CORRECTION

The following errors were noted in comparing the printed patent with the papers in the attorneys' files:

In the Specification:

Column 5, line 63, "circles) B" should read -- circles). B--.

Column 6, line 8, "130 m²" should read --130 mm²--.

Column 6, line 11, "100 µl/dose,x36" should read --100 µl/dose x36--.

Column 7, line 24, "(10x10⁶ cell/mouse)" should read --(10x10⁶ cell/mouse)--.

Column 7, line 44, "120-1 80" should read -- 120-180--.

Column 14, line 33, "pH 83" should read -- pH 8.3--.

Column 14, line 37, "Na₂ HPO₄" should read --Na₂HPO₄--.

Column 14, line 38, "factions" should read --fractions--.

- Column 15, line 12, “8M” should read --8 M--.
- Column 16, line 54 “pelleted. and” should read --pelleted, and--.
- Column 16, line 66, “kinetic-QCL assay” should read -- kinetic-QCLTM assay--.
- Column 18, line 9, “(25 mg/ml)” should read -- (25 ng/ml)--.
- Column 18, line 17, “triplicate” should read -- triplicate.--.
- Column 18, line 18, “triplicate” should read -- triplicate.--.
- Column 18, line 19, “mean” should read -- mean.--.
- Column 22, line 11, Table 4, is missing the “Inhibition percentage value” for the first line. Thus, “1.^a None 142 ” should read --1.^a None 142 44--.
- Column 23, line 30, “days/week,” should read --“days/week);--.
- Column 23, line 45, “(FIG. 3D).” should read --(FIG 3D),--.
- Column 24, line 10. “tumor” should read --tumors--.
- Column 25, line 20, “(30 µg/day,” should read --(30 µg/day);--.
- Column 26, line 12, “red” should read --rad.--.
- Column 26, line 54, “Vivo” should read --Vivo,--.
- Column 26, line 57, “turner” should read --tumor--.
- Column 27, line 16, “Interleukin-12” should read --Interleukin-12.--.
- Column 28, line 19, “10)” should read -- 10).--.
- Column 28, line 33 “amino jet acid” should read --amino acid--.
- Column 31, line 3 “fist” should read --first--.
- Column 32, line 23 “supra (Seq.” should read --supra) (Seq.--.
- Column 33, line 44, “may be” should read --may--.
- Column 33, line 45, “may be” should read --may--.
- Column 33, line 62, “(IN)γ,” should read --IFN)γ,--.
- Column 34, line 61, “treatment diseases” should read --treatment of diseases--.

In the Claims:

- Column 61, Claim 18, line 40, “(TNF)α,” should read --(TNF)-α,--.

Since not all of the errors are attributable to the Patent Office, enclosed is the fee of \$100.00 pursuant to 37 C.F.R. 1.20(a). The preceding corrections remedy mistakes of a typographical nature and/or minor character. A proposed Certificate of Correction is enclosed to make formal notice of the errors in the referenced patent. Applicants request that the Patent Office provide a formal Certificate of Correction to correct the errors noted herein.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630

cc: Docketing/Client